ERK signaling in colorectal cancer: A preliminary report on the expression of phosphorylated ERK and the effects of radiation therapy

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 31, Issue 3, 2008, Pages 255-258

  Corn, Benjamin W ^a   Kovner, Felix ^a   Bek, Stella ^a   Wexler, Isaiah ^b   Lifschits, Beatrice ^a   Seger, Rony ^c  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^c WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

Colorectal cancer; ERK; MAPK; Radiation therapy

Indexed keywords

ANTIBODY; MITOGEN ACTIVATED PROTEIN KINASE; TUMOR MARKER;

ARTICLE; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; ENZYME PHOSPHORYLATION; HISTOLOGY; HUMAN; HUMAN TISSUE; OUTCOME ASSESSMENT; PILOT STUDY; PROTEIN EXPRESSION; RADIATION RESPONSE; RECTUM CARCINOMA; SIGNAL TRANSDUCTION; STAINING; ADENOCARCINOMA; BIOPSY; CANCER STAGING; COLORECTAL TUMOR; ENZYMOLOGY; IMMUNOHISTOCHEMISTRY; METABOLISM; PATHOLOGY; PHOSPHORYLATION; PROGNOSIS;

ADENOCARCINOMA; BIOPSY; COLORECTAL NEOPLASMS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM STAGING; PHOSPHORYLATION; PILOT PROJECTS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 44949169682     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e31815a5647     Document Type: Article

References (19)

1. Yoon S, Seger R. The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions. Growth Factors. 2006;24: 21-44.
2. Shaul YD, Seger R. The MEK/ERK cascade: From signaling specificity to diverse functions. Biochim Biophys Acta. 2006; Epub ahead of print.
3. Wolf I, Seger R. The mitogen-activated protein kinase signaling cascade: from bench to bedside. Isr Med Assoc J. 2002;4:641-647.
4. Hoshino R, Chatani Y, Yamori T, et al. Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene. 1999;18:813-822.
5. Diaz VM, Hurtado M, Kort EJ, et al. Requirement of the enzymatic and signaling activities of plasmin for phorbol-ester-induced scattering of colon cancer cells. Exp Cell Res. 2006;312:2203-2213.
6. Park KS, Jeon SH, Kim SE, et al. APC inhibits ERK pathway activation and cellular proliferation induced by RAS. J Cell Sci. 2006;119:819- 827.
7. Liu Y, Borchert GL, Surazynski A, et al. Proline oxidase activates both intrinsic and extrinsic pathways for apoptosis: the role of ROS/superox-ides, NFAT and MEK/ERK signaling. Oncogene. 2006;25:5640-5647.
8. Landis SH, Murray T, Bolden S, et al. Cancer statistics, 1998. CA Cancer J Clin. 1998;48:6-29.
9. Zhu F, Zykova TA, Kang BS, et al. Bidirectional signals transduced by TOPK-ERK interaction increase tumorigenesis of HCT116 colorectal cancer cells. Gastroenterology. 2007;133:219-231.
10. Swedish Rectal Cancer Trial. Improved survival with preoperative radiotherapy in resectable rectal Cancer. N Engl J Med. 1997;336:980- 987.
11. Yeoh AS, Bowen JM, Gibson RJ, et al. Nuclear factor kappaB (NFkappaB) and cyclooxygenase-2 (Cox-2) expression in the irradiated colorectum is associated with subsequent histopathological changes. Int J Radiat Oncol Biol Phys. 2005;63:1295-1303.
12. Bonner JA, Vroman BT, Christianson TJ, et al. Ionizing radiation-induced MEK and Erk activation does not enhance survival of irradiated human squamous cell carcinoma cells. Int J Radiat Oncol Biol Phys. 1998;42:921-925.
13. Dent P, Yacoub A, Fisher PB, et al. MAPK pathways in radiation responses. Oncogene. 2003;22:5885-5896.
14. Wang T, Hu YC, Dong S, et al. Co-activation of ERK, NF KappaB and GADD45beta in response to ionizing radiation. J Biol Chem. 2005;280: 12593-12601.
15. Watanabe H, Kurabayashi T, Miura M. Inhibition of the extracellular signal-regulated kinase (ERK) pathway and the induction of radioresis-tance in rat 3Y1 cells. Int J Radiat Biol. 2004;80:451-457.
16. Seong J, Kim S, Suh C. Enhancement of radioresponse of murine tumors by ERK inhibitor. Ann NY Acad Sci. 2002;973:371-373.
17. LoRusso PM, Adjei AA, Varterasian M, et al. Phase I and pharmaco-dynamic study of oral MEK inhibitor CI-1040 in patients with advanced malignancies. J Clin Oncol. 2005;23:5281-5293.
18. Sebolt-Leopold JS, Dudley DT, Herrera R, et al. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat Med. 1999;5:810-816.
19. LoRusso PM, Krishnaumurthy S, Rinhart J, et al. A phase 1-2 clinical study of a second generation oral MEK inhibitor PD 0325901 in patients with advanced Cancer. Proc Am Soc Clin Oncol. 2005;23:194s(abstract 3011).